We have observed an increase in the number of carbapenemresistant S. marcescens isolates in blood cultures in our laboratory in the KwaZulu-Natal (KZN) region, South Africa, which is particularly worrisome, given that Serratia species are inherently resistant to colistin.
During 2017, S. marcescens was the 6th most common isolate in blood cultures. Of the 572 Enterobacteriaceae isolated from blood cultures, S. marcescens was the 3rd most common after E. coli and K. pneumo niae, accounting for 11% (63/572) of isolates. Ten S. marces cens isolates were carbapenem resistant; 7 of these were also resistant to tigecycline, thus making them pan drug resistant. All the carbapenemresistant S. marcescens isolates carried the New Delhi metallo-betalactamase 1 (NDM1) gene. Unlike other reports of S. marcescens bacteraemia, these isolates were from several different hospitals across KZN and were not linked to an outbreak. [4, 5] The emergence of pan drug-resistant S. marcescens in blood cultures in this region creates a challenge for the management of patients admitted to hospitals and intensive care units. Implementation of antimicrobial stewardship and strict infection control practices is imperative to prevent further dissemination of this formidable pathogen. 
